Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Biliary Tract Diseases

  Free Subscription

Articles published in J Hepatol

Retrieve available abstracts of 184 articles:
HTML format

Single Articles

    September 2021
  1. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available

  2. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available

    August 2021
  3. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.

  4. DE JONG IEM, van den Heuvel MC, Wells RG, Porte RJ, et al
    The heterogeneity of the biliary tree.
    J Hepatol. 2021 Aug 19. pii: S0168-8278(21)00251.

    July 2021
  5. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available

  6. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.

  7. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.

    June 2021
  8. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available

  9. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.

  10. ZHANG Y, Zuo C, Liu L, Hu Y, et al
    Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
    PubMed     Abstract available

    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.

    May 2021
  12. SONG X, Xu H, Wang P, Wang J, et al
    Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
    PubMed     Abstract available

  13. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available

  14. BOULTER L, Ebrahimkhani MR
    Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
    J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.

  15. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.

  16. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available

    April 2021
  17. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available

  18. REICH M, Spomer L, Klindt C, Fuchs K, et al
    Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
    PubMed     Abstract available

  19. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
    FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
    J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
    PubMed     Abstract available

    March 2021
  20. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available

  21. DELTENRE P, Moreno C, Trepo E
    Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
    J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.

  22. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available

  23. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
    FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
    PubMed     Abstract available

    February 2021
  24. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.

  25. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.

  26. BOYER JL, Soroka CJ
    Bile formation and Secretion: An update.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
    PubMed     Abstract available

  27. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.

  28. CASOLINO R, Braconi C
    CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.

  29. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.

  30. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
    Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
    J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.

  31. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.

  32. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available

  33. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available

    January 2021
  34. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available

    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.

  36. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available

  37. RAGGI C, Taddei ML, Sacco E, Navari N, et al
    Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
    PubMed     Abstract available

  38. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.

  39. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.

    December 2020
  40. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.

  41. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.

  42. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available

  43. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available

  44. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
    Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
    PubMed     Abstract available

    November 2020
  45. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
    TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
    PubMed     Abstract available

  46. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available

  47. STEIN S, Henze L, Poch T, Carambia A, et al
    IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
    PubMed     Abstract available

    October 2020
  48. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available

  49. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.

  50. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.

  51. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available

    September 2020
  52. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    PubMed     Abstract available

  53. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    PubMed     Abstract available

  54. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.

  55. BALAPHAS A, Gkoufa K, Meyer J, Peloso A, et al
    Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30550.

  56. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.

    August 2020
  57. IZURIETA PACHECO AC, Monfort Carretero L, Prat Torres C, Garcia-Alix Perez A, et al
    NISCH syndrome: An extremely rare cause of neonatal cholestasis.
    J Hepatol. 2020 Aug 27. pii: S0168-8278(20)30459.

    July 2020
  58. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available

  59. CARBONE M, Milani C, Gerussi A, Ronca V, et al
    Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30362.

  60. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.

    Effective medical treatments for PSC needed ASAP - is AESOP the answer?
    J Hepatol. 2020;73:12-14.

    June 2020
  62. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available

  63. BREVINI T, Tysoe OC, Sampaziotis F
    Tissue engineering of the biliary tract and modelling of cholestatic disorders.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30367.
    PubMed     Abstract available

  64. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available

  65. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.

  66. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.

    May 2020
  67. MCNAMARA MG, Lopes A, Wasan H, Malka D, et al
    Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30306.
    PubMed     Abstract available

  68. JACKSON SS, Adami HO, Andreotti G, Beane-Freeman LE, et al
    Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30292.
    PubMed     Abstract available

  69. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available

    April 2020
  70. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available

    March 2020
  71. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.

  72. JIANG M, Deng H, Liu S, Su S, et al
    Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30067.

  73. MONTAL R, Sia D, Montironi C, Leow WQ, et al
    Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Mar 12. pii: S0168-8278(20)30166.
    PubMed     Abstract available

  74. LAMARCA A, Barriuso J, McNamara MG, Valle JW, et al
    Molecular targeted therapies: ready for "prime time" in biliary tract cancer.
    J Hepatol. 2020 Mar 11. pii: S0168-8278(20)30165.
    PubMed     Abstract available

  75. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available

    February 2020
  76. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available

  77. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    PubMed     Abstract available

  78. KELLEY RK, Bridgewater J, Gores GJ, Zhu AX, et al
    Systemic therapies for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:353-363.
    PubMed     Abstract available

    January 2020
  79. PANZITT K, Jungwirth E, Krones E, Lee JM, et al
    FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    J Hepatol. 2020 Jan 27. pii: S0168-8278(20)30031.
    PubMed     Abstract available

    December 2019
  80. DE VRIES E, Beuers U
    Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"
    J Hepatol. 2019 Dec 28. pii: S0168-8278(19)30705.

  81. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available

  82. KUMAR P, Kulkarni A
    UDCA therapy in intrahepatic cholestasis of pregnancy?
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30653.

  83. PEI T, Meng F, Xiao P, Han J, et al
    MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    J Hepatol. 2019 Dec 11. pii: S0168-8278(19)30713.
    PubMed     Abstract available

    October 2019
  84. MEUNIER L, Meszaros M, Pageaux GP, Larrey D, et al
    Potential role of ketamine in burn-associated cholestasis.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30475.

    September 2019
  85. LEGRAND M, de Tymowski C, Hodjat K, Mallet V, et al
    Reply to: "Potential role of ketamine in burn-associated cholestasis".
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30542.

  86. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30527.

  87. KHANDEKAR G, Llewellyn J, Kriegermeier A, Waisbourd-Zinman O, et al
    Coordinated development of the mouse extrahepatic bile duct: implications for neonatal susceptibility to biliary injury.
    J Hepatol. 2019 Sep 25. pii: S0168-8278(19)30550.
    PubMed     Abstract available

  88. KHAN SA, Genus T, Morement H, Murphy A, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30466.

  89. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available

    Risk stratification in primary sclerosing cholangitis: It's time to move on from replicating imperfection and break the glass ceiling.
    J Hepatol. 2019 Sep 9. pii: S0168-8278(19)30480.

    August 2019
  91. SHETTY S, Boyer JL
    Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic.
    J Hepatol. 2019 Aug 22. pii: S0168-8278(19)30420.

    July 2019
  92. GOET JC, Floreani A, Verhelst X, Cazzagon N, et al
    Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.
    J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384.
    PubMed     Abstract available

    June 2019
  93. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    PubMed     Abstract available

  94. GLASER F, John C, Engel B, Hoh B, et al
    Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
    J Hepatol. 2019 Jun 14. pii: S0168-8278(19)30347.
    PubMed     Abstract available

  95. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    PubMed     Abstract available

  96. ZHOU G, Sprengers D, Mancham S, Erkens R, et al
    Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex-vivo targeting immune checkpoint molecules.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30340.
    PubMed     Abstract available

  97. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    PubMed     Abstract available

    May 2019
  98. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    PubMed     Abstract available

  99. DE KRIJGER M, Wildenberg ME, de Jonge WJ, Ponsioen CY, et al
    Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30287.
    PubMed     Abstract available

  100. NISHIO T, Hu R, Koyama Y, Liang S, et al
    Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30273.
    PubMed     Abstract available

    April 2019
  101. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    PubMed     Abstract available

  102. ALEKSIEVA N, Forbes SJ
    Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30185.

  103. OVEREEM AW, Klappe K, Parisi S, Kloters-Planchy P, et al
    Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30225.
    PubMed     Abstract available

    March 2019
  104. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    PubMed     Abstract available

  105. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Mar 22. pii: S0168-8278(19)30183.
    PubMed     Abstract available

  106. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    PubMed     Abstract available

  107. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    PubMed     Abstract available

    February 2019
  108. LAMARCA A, Barriuso J, Chander A, McNamara MG, et al
    18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30126.
    PubMed     Abstract available

  109. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    PubMed     Abstract available

  110. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.

    January 2019
  111. SCHMIDT T, Schwinge D, Rolvien T, Jeschke A, et al
    Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.
    J Hepatol. 2019 Jan 11. pii: S0168-8278(19)30016.
    PubMed     Abstract available

  112. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    PubMed     Abstract available

  113. TABIBIAN JH, Lindor KD
    NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter.
    J Hepatol. 2019 Jan 6. pii: S0168-8278(18)32623.

    December 2018
  114. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Abstract available

  115. CADAMURO M, Brivio S, Mertens J, Vismara M, et al
    Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32620.
    PubMed     Abstract available

  116. LEE S, Kim MJ, Kim S, Choi D, et al
    Intraductal Papillary Neoplasm of the Bile Duct: Assessment of Invasive Carcinoma and Long-Term Outcomes using MRI.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32621.
    PubMed     Abstract available

    November 2018
  117. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Abstract available

    October 2018
  118. DE HAAN LR, van Golen RF
    Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
    J Hepatol. 2018 Oct 4. pii: S0168-8278(18)32382.

    September 2018
  119. TANAKA H, Imasato M, Yamazaki Y, Matsumoto K, et al
    Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone cores formation in mice.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32374.
    PubMed     Abstract available

  120. RODRIGUES PM, Perugorria MJ, Santos-Laso A, Bujanda L, et al
    Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32362.
    PubMed     Abstract available

    August 2018
  121. CUBERO FJ, Peng J, Liao L, Su H, et al
    Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32297.
    PubMed     Abstract available

  122. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Abstract available

    July 2018
  123. PROBERT PM, Leitch AC, Dunn MP, Meyer SK, et al
    Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32182.
    PubMed     Abstract available

  124. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Abstract available

    June 2018
  125. BRINKERT F, Pukite I, Krebs-Schmitt D, Briem-Richter A, et al
    Allogeneic hematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency.
    J Hepatol. 2018 Jun 20. pii: S0168-8278(18)32156.
    PubMed     Abstract available

  126. YANG L, Mizuochi T, Shivakumar P, Mourya R, et al
    Regulation of Epithelial Injury and Bile Duct Obstruction by NLRP3 and IL-1R1 in Experimental Biliary Atresia.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32123.
    PubMed     Abstract available

    May 2018
  127. GUICCIARDI ME, Trussoni CE, Krishnan A, Bronk SF, et al
    Macrophages Contribute to the Pathogenesis of Sclerosing Cholangitis in Mice.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32064.
    PubMed     Abstract available

  128. PEERAPHATDIT TB, Simonetto DA, Shah VH
    Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.
    J Hepatol. 2018 May 21. pii: S0168-8278(18)32058.

  129. LIU HC, Hu XS, Pang Q, Jin H, et al
    Potential limitations of irradiation stent implantation in unresectable malignant biliary obstruction.
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32021.

  130. ZHU HD, Lu J, Teng GJ
    Response to Letter to the Editor on "Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial".
    J Hepatol. 2018 May 8. pii: S0168-8278(18)32049.

    April 2018
  131. POLLHEIMER MJ, Racedo S, Mikels-Vigdal A, Marshall D, et al
    Lysyl oxidase-like protein 2 (LOXL2) Modules Barrier Function in Cholangiocytes In Cholestasis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32017.
    PubMed     Abstract available

  132. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Abstract available

    March 2018
  133. SETO WK, Mak SK, Chiu K, Vardhanabhuti V, et al
    Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30164.
    PubMed     Abstract available

  134. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Abstract available

  135. SCHNEIDER KM, Albers S, Trautwein C
    Role of bile acids in the gut-liver axis.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(17)32450.

    February 2018
  136. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.

  137. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.

  138. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Abstract available

  139. KABASHIMA A, Hirsova P, Bronk SF, Hernandez MC, et al
    Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30073.
    PubMed     Abstract available

    January 2018
  140. WARDELL CP, Fujita M, Yamada T, Simbolo M, et al
    Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations.
    J Hepatol. 2018 Jan 19. pii: S0168-8278(18)30021.
    PubMed     Abstract available

  141. ZHU HD, Guo JH, Huang M, Ji JS, et al
    Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30012.
    PubMed     Abstract available

    December 2017
  142. JIROUSKOVA M, Nepomucka K, Oyman-Eyrilmez G, Kalendova A, et al
    Plectin Controls Biliary Tree Architecture and Stability in Cholestasis.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32495.
    PubMed     Abstract available

    November 2017
  143. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Abstract available

  144. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Abstract available

    September 2017
  145. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.

  146. WU H, Zhang H, Hu LY, Zhang TY, et al
    Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32269.

  147. LOOSEN SH, Roderburg C, Luedde T
    Reply to: "Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?"
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32267.

    August 2017
    Sequencing of transporter genes in cholestasis: we are still learning.
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32213.

  149. KARLSEN TH, Folseraas T, Thorburn D, Vesterhus M, et al
    Primary sclerosing cholangitis - a comprehensive review.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32196.
    PubMed     Abstract available

    July 2017
  150. DROGE C, Bonus M, Baumann U, Klindt C, et al
    Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32147.
    PubMed     Abstract available

  151. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Abstract available

  152. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Abstract available

  153. SCHERBER PR, Lammert F, Glanemann M
    Gallstone disease: Optimal timing of treatment.
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)30214.

  154. TRIVEDI PJ, Scalera I, Slaney E, Laing RW, et al
    Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32135.
    PubMed     Abstract available

    Norursodeoxycholic acid in patients with primary sclerosing cholangitis: a new "urso saga" in the horizon?
    J Hepatol. 2017 Jul 1. pii: S0168-8278(17)32132.

    June 2017
  156. LOOSEN SH, Roderburg C, Kauertz KL, Pombeiro I, et al
    Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    J Hepatol. 2017 Jun 28. pii: S0168-8278(17)32121.
    PubMed     Abstract available

    May 2017
  157. FICKERT P, Hirschfield GM, Denk G, Marschall HU, et al
    norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis.
    J Hepatol. 2017 May 18. pii: S0168-8278(17)32045.
    PubMed     Abstract available

    April 2017
    Reply to: Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30253.

  159. CHEUNG AC, Juran BD, Moore RM, LaRusso NF, et al
    Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30254.

  160. HIRSCHFIELD GM, Beuers U, Corpechot C, Invernizzi P, et al
    EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
    J Hepatol. 2017 Apr 17. pii: S0168-8278(17)30186.
    PubMed     Abstract available

  161. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.
    J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30108.
    PubMed     Abstract available

  162. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Abstract available

  163. RIZVI S, Gores GJ
    Emerging Molecular Therapeutic Targets for Cholangiocarcinoma.
    J Hepatol. 2017 Apr 4. pii: S0168-8278(17)30197.
    PubMed     Abstract available

    March 2017
  164. JULICH-HAERTEL H, Urban SK, Krawczyk M, Willms A, et al
    Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30123.
    PubMed     Abstract available

  165. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Abstract available

    February 2017
  166. ORNTOFT NW, Munk OL, Frisch K, Ott P, et al
    Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positrion Emission Tomography (PET).
    J Hepatol. 2017 Feb 26. pii: S0168-8278(17)30120.
    PubMed     Abstract available

  167. KRONES E, Eller K, Pollheimer MJ, Racedo S, et al
    NorUrsodeoxycholic Acid Ameliorates Cholemic Nephropathy in Bile Duct Ligated Mice.
    J Hepatol. 2017 Feb 24. pii: S0168-8278(17)30116.
    PubMed     Abstract available

  168. MERINO-AZPITARTE M, Lozano E, Perugorria MJ, Esparza-Baquer A, et al
    SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumor Suppressor in Cholangiocarcinoma.
    J Hepatol. 2017 Feb 22. pii: S0168-8278(17)30114.
    PubMed     Abstract available

  169. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Abstract available

  170. GUPTA K, Li Q, Fan JJ, Fong EL, et al
    Actomyosin Contractility Drives Bile Regurgitation as an Early Response During Obstructive Cholestasis.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30061.
    PubMed     Abstract available

  171. VESTERHUS M, Holm A, Hov JR, Nygard S, et al
    Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30052.
    PubMed     Abstract available

    January 2017
  172. MOEINI A, Sia D, Zhang Z, Camprecios G, et al
    Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30014.
    PubMed     Abstract available

  173. HANLEY J, Kumar Dhar D, Mazzacuva F, Fiadeiro R, et al
    Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30005.
    PubMed     Abstract available

  174. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
    J Hepatol. 2017;66:254.

    December 2016
  175. SCHWINGE D, von Haxthausen F, Quaas A, Carambia A, et al
    Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30705.
    PubMed     Abstract available

    November 2016
  176. MONTE MJ, Alonso-Pena M, Briz O, Herraez E, et al
    ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30652.
    PubMed     Abstract available

  177. LOFFLER MW, Chandran PA, Laske K, Schroeder C, et al
    Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30613.

    October 2016
  178. RICKE J, Seidensticker M
    Molecular imaging and liver function assessment by hepatobiliary MRI.
    J Hepatol. 2016 Oct 8. pii: S0168-8278(16)30566.

  179. SCHRUMPF E, Kummen M, Valestrand L, Greiner TU, et al
    The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30559.
    PubMed     Abstract available

  180. FICKERT P
    Bad memories from the gut may cause nightmares for the bile ducts - "Nothing fixes a thing so intensely in the memory as the wish to forget it.": Editorial for: "Gut and liver T cells of common clonal origin are detected in primary sclerosing cholangi
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30543.

    September 2016
  181. VAQUERO J, Guedj N, Claperon A, Ho-Bouldoires TH, et al
    Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30537.
    PubMed     Abstract available

  182. HENRIKSEN EK, Jorgensen KK, Kaveh F, Holm K, et al
    Gut and liver T cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
    J Hepatol. 2016 Sep 16. pii: S0168-8278(16)30503.
    PubMed     Abstract available

    April 2016
  183. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Abstract available

    January 2016
  184. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease.
    J Hepatol. 2016;64.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.